US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Keryx Biopharmaceuticals

3.36

0.0000

Volume:- -

Turnover:- -

Market Cap:404.46M

PE:-4.49

High:3.36

Open:3.36

Low:3.36

Close:3.36

52wk High:5.98

52wk Low:2.47

Shares:120.38M

Float Shares:82.15M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7491

EPS(LYR):-1.4273

ROE:--

ROA:--

PB:-7.46

PE(LYR):-2.35

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Keryx Biopharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.keryx.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KERX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KERX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KERX\",,,,,undefined,":{"symbol":"KERX","market":"US","secType":"STK","nameCN":"Keryx Biopharmaceuticals","latestPrice":3.36,"timestamp":1575925200000,"preClose":3.36,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":82153320,"shares":120375926,"eps":-0.749112,"marketStatus":"Delisted","change":0,"latestTime":"02-19 10:25:33 EST","open":3.36,"high":3.36,"low":3.36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.749112,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":964756800000,"exchange":"NASDAQ","adjPreClose":3.36,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KERX\",,,,,undefined,":{"symbol":"KERX","floatShares":82153320,"roa":"--","roe":"--","lyrEps":-1.427327,"shares":120375926,"dividePrice":0,"high":3.36,"amplitude":0,"preClose":3.36,"low":3.36,"week52Low":2.47,"pbRate":"-7.46","week52High":5.98,"institutionHeld":0.9467,"latestPrice":3.36,"eps":-0.749112,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.749112,"open":3.36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KERX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"KERX","fiscalQuarterEnding":"2018/09","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2018-08-08","symbol":"KERX","expectedEps":-0.14,"name":"克律克斯生物制药","time":"Pre-Market","type":"earning","dateTimestamp":1533700800000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2018-05-10","symbol":"KERX","fiscalQuarterEnding":"2018/03","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2018-02-07","symbol":"KERX","fiscalQuarterEnding":"2017/12","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1517979600000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2017-11-07","symbol":"KERX","expectedEps":-0.17,"name":"克律克斯生物制药","time":"","type":"earning","dateTimestamp":1510030800000,"reportTimeType":"","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KERX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KERX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.keryx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.","exchange":"NASDAQ","name":"Keryx Biopharmaceuticals","nameEN":"Keryx Biopharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KERX\",market:\"US\",,,undefined,":null}}